The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Efficacy and safety of once-weekly semaglutide 2.0 mg vs 1.0 mg by baseline HbA1c and BMI: SUSTAIN FORTE subgroup analyses
John B. Buse1; Harpreet S. Bajaj2; Yasushi Fukushima3; Ildiko Lingvay4; Stanislava Macura5; Anette L. Søndergaard5; Tsvetalina I. Tankova6; Nikolaos Tentolouris7; Juan Pablo Frias8;
1 Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 2 LMC Diabetes and Endocrinology, Brampton, ON, Canada; 3 Fukuwa Clinic, Tokyo, Japan; 4 Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA; 5 Novo Nordisk A/S, Søborg, Denmark; 6 Department of Endocrinology, Medical University of Sofia, Sofia, Bulgaria; 7 Diabetology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, "Laiko" General Hospital, Athens, Greece; 8 Clinical Research, National Research Institute, Los Angeles, CA, USA;